Monitor future Form 4 filings from McDonnell for any open-market purchases or sales, which would provide a clearer signal on insider conviction. No immediate trading implications from this filing alone.
MRNA drugs
MRNA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 13 $67.01entry
- T+1 · 4mo ago +0.64%α +0.29% · $67.44
- T+5 · 4mo ago −7.75%α −6.96% · $61.82
- T+20 · 3mo ago −10.74%α −13.93% · $59.81
- T+60 · 6w ago +179.75%α +175.76% · $187.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Michael McDonnell filed a Form 3 initial statement of beneficial ownership with Moderna, indicating he has become an officer or director. The filing is a routine administrative requirement and contains no transaction or holding details.
Key Facts
- Form 3 filed by Michael McDonnell as a new reporting person at Moderna.
- No securities holdings or transactions disclosed in the filing.
- Power of attorney executed on July 8, 2026, authorizing officers to file Section 16 forms.
Financial Impact
No financial impact; routine insider onboarding filing.
Risk Factors
- No material risks identified from this administrative filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001682852-26-000137 |
| Document: 0001682852-26-000137-index-headers.html | 0001682852-26-000137 |
| Document: 0001682852-26-000137-index.html | 0001682852-26-000137 |
| Document: 0001682852-26-000137.txt | 0001682852-26-000137 |
Track record
26 reports on MRNA
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
- Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
- Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
- Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
- Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers